Literature DB >> 19432111

[Bone metabolic marker for osteoporosis].

Kaori Shidara1, Masaaki Inaba.   

Abstract

The purposes hypothesized for the determination of bone metabolic markers, among which we can measure serum BAP, NTX, TRAP-5b or urinary NTX, DPD, CTX in routine clinical practice, are to predict the rate of bone loss and the resultant fracture risk, and to estimate bone quality. The higher value of bone markers, which might reflect high turnover bone disease, allows us to discriminate those who require early introduction of drug therapy such as bisphosphonate, and raloxifene. Furthermore, early reduction of bone resorption markers, but not bone formation markers, possibly 3-6 month after initiation of bone anti-resorptive drugs, enables us to predict bone gain thereafter. Among various bone resorption markers, TRAP-5b might be the best in that it is not susceptible to between-day variation, day-to-day variation, and renal dysfunction resulting from chronic kidney disease which often occurs in osteoporosis-prone elderly women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432111

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  3 in total

Review 1.  The assessment of fracture risk.

Authors:  Aasis Unnanuntana; Brian P Gladnick; Eve Donnelly; Joseph M Lane
Journal:  J Bone Joint Surg Am       Date:  2010-03       Impact factor: 5.284

2.  Estradiol and zinc-doped nano hydroxyapatite as therapeutic agents in the prevention of osteoporosis; oxidative stress status, inflammation, bone turnover, bone mineral density, and histological alterations in ovariectomized rats.

Authors:  Mona M Elghareeb; Gehad E Elshopakey; Tarek A Elkhooly; Basma Salama; Alaa Samy; Fuller W Bazer; Mohammed A Elmetwally; Mikhlid H Almutairi; Lotfi Aleya; Mohamed M Abdel-Daim; Shaymaa Rezk
Journal:  Front Physiol       Date:  2022-09-19       Impact factor: 4.755

Review 3.  Effects of ginsenosides on bone remodelling for novel drug applications: a review.

Authors:  Nan Yang; Dingkun Liu; Xiao Zhang; Jianing Li; Mi Wang; Tongtong Xu; Zhihui Liu
Journal:  Chin Med       Date:  2020-05-06       Impact factor: 5.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.